Abstract This article analyzes the financial framework shaping CAR-T cell therapy manufacturing across Oman and the Gulf Cooperation Council. It
Abstract This article analyzes the transformation of Oman’s and the GCC’s pharmaceutical oversight systems through enhanced data integrity and digitized
Oman’s Launch Pad: How OBP Is Building the Region’s Flagship for Biologics and Cell/Gene Therapy Oman is entering a decisive
From Apheresis to Infusion: How Operational Speed Shapes Returns in GCC Advanced Therapy Manufacturing The Gulf’s life sciences sector
Building a Regional Center of Excellence in Oman’s Biopharma Sector: Jobs, Training, and Export Potential Oman is quietly shaping
First-Mover Edge in Muscat: Unlocking the Oman↔KSA Corridor for Advanced Therapies INTRODUCTION — CAR-T investment GCC: why a Muscat-anchored Oman–KSA
Introduction The realm of oncology in The Middle East and North Africa (MENA) is a narrative of constant evolution, striving to meet the growing demands
Introduction The realm of oncology in The Middle East and North Africa (MENA) is a narrative of constant evolution, striving to meet the growing demands
Introduction The realm of oncology in The Middle East and North Africa (MENA) is a narrative of constant evolution, striving to meet the growing demands
Introduction The realm of oncology in The Middle East and North Africa (MENA) is a narrative of constant evolution, striving to meet the growing demands
Introduction The realm of oncology in The Middle East and North Africa (MENA) is a narrative of constant evolution, striving to meet the growing demands
Introduction The realm of oncology in The Middle East and North Africa (MENA) is a narrative of constant evolution, striving to meet the growing demands
